The Journal of Pediatrics
Volume 151, Issue 2 , Pages 115-120.e3 , August 2007

Cost-Effectiveness of Neonatal Screening for Medium Chain acyl-CoA Dehydrogenase Deficiency: The Homogeneous Population of the Netherlands

  • Christian S. van der Hilst, MSc

      Affiliations

    • Office for Medical Technology Assessment, University of Groningen, University Medical Center Groningen, The Netherlands
    • Corresponding Author InformationReprint requests: Christian S. van der Hilst, MSc, Office for Medical Technology Assessment, University Medical Center Groningen, PO Box 30 001, 9700 RB Groningen, The Netherlands.
    • ,
  • Terry G.J. Derks, MD, PhD

      Affiliations

    • Division of Metabolic Diseases, Beatrix Children’s Hospital, University of Groningen, University Medical Center Groningen, The Netherlands
    • ,
  • Dirk-Jan Reijngoud, PhD

      Affiliations

    • Laboratory of Metabolic Diseases, Beatrix Children’s Hospital, University of Groningen, University Medical Center Groningen, The Netherlands.
    • ,
  • G. Peter A. Smit, MD, PhD

      Affiliations

    • Division of Metabolic Diseases, Beatrix Children’s Hospital, University of Groningen, University Medical Center Groningen, The Netherlands
    • ,
  • Elisabeth M. TenVergert, PhD

      Affiliations

    • Office for Medical Technology Assessment, University of Groningen, University Medical Center Groningen, The Netherlands

Received 19 July 2006 ,Revised 1 February 2007 ,Accepted 6 March 2007.

References 

  1. Roe CR, Ding J. Mitochondrial fatty acid oxidation disorders. In:  Scriver CR,  Beaudet AL,  Sly WS,  Valle D editor. The metabolic and molecular bases of inherited diseases. New York: McGraw-Hill; 2001;p. 2297–2326
  2. Iafolla AK, Thompson RJ, Roe CR. Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr. 1994;124:409–415
  3. Vianey-Liaud C, Divry P, Gregersen N, Mathieu M. The inborn errors of mitochondrial fatty acid oxidation. J Inherit Metab Dis. 1987;10(Suppl 1):159–200
  4. Touma EH, Charpentier C. Medium chain acyl-CoA dehydrogenase deficiency. Arch Dis Child. 1992;67:142–145
  5. Wilcken B, Hammond J, Silink M. Morbidity and mortality in medium chain acyl coenzyme A dehydrogenase deficieny. Arch Dis Child. 1994;70:410–412
  6. Wilson CJ, Champion MP, Collins JE, Clayton PT, Leonard JV. Outcome of medium chain acyl-CoA dehydrogenase deficiency after diagnosis. Arch Dis Child. 1999;80:459–462
  7. Pollitt RJ, Leonard JV. Prospective surveillance study of medium chain acyl-CoA dehydrogenase deficiency in the UK. Arch Dis Child. 1998;79:116–119
  8. Wilcken B, Haas M, Joy P, Wiley V, Chaplin M, Black C, et al. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet. 2007;369:37–42
  9. De Vries HG, Niezen-Koning K, Kliphuis JW, Smit GPA, Scheffer H, Ten Kate LP. Prevalence of carriers of the most common medium-chain acyl-CoA dehydrogenase (MCAD) deficiency mutation (G985A) in The Netherlands. Hum Genet. 1996;98:1–2
  10. Derks TGJ, Duran M, Waterham HR, Reijngoud DJ, Ten Kate LP, Smit GPA. The difference between observed and expected prevalence of MCAD deficiency in The Netherlands: a genetic epidemiological study. Eur J Hum Genet. 2005;13:947–952
  11. Derks TGJ, Reijngoud DJ, Waterham HR, Gerver WJM, Van den Berg MP, Sauer PJJ, et al. The natural history of medium-chain acyl CoA dehydrogenase deficiency in The Netherlands: Clinical presentation and outcome. J Pediatr. 2006;148:665–670
  12. Wilson JMG, Jungner G. Principles and practice of screening for disease (Public health papers no. 34). Geneva: World Health Organization; 1968;
  13. Rashed MS, Ozand PT, Bucknall MP, Little D. Diagnosis of inborn errors of metabolism from blood spots by acylcarnitines and amino acids profiling using automated electrospray tandem mass spectrometry. Pediatr Res. 1995;38:324–331
  14. Clayton PT, Doig M, Ghafari S, Meaney C, Taylor C, Leonard JV, et al. Screening for medium-chain acyl-CoA dehydrogenase deficiency using electrospray ionisation tandem mass spectrometry. Arch Dis Child. 1998;79:109–115
  15. Chace DH, Hillmann SL, Van Hove JLK, Naylor EW. Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem. 1997;43:2106–2113
  16. Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess. 2004;8(12):1–121
  17. Venditti LN, Venditti CP, Berry GT, Kaplan PB, Kaye EM, Glick H, et al. Newborn screening by tandem mass spectrometry for medium-chain acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics. 2003;112:1005–1015
  18. Insinga RP, Laessig RH, Hoffman GL. Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel. J Pediatr. 2002;141:524–531
  19. Duran M, Mitchell G, De Klerk JB, De Jager JP, Hofkamp M, Bruinvis L, et al. Octanoic acidemia and octanoylcarnitine excretion with dicarboxylic aciduria due to defective oxidation of medium-chain fatty acids. J Pediatr. 1985;107:397–404
  20. Duran M, Ketting D, Van Vossen R, Beckeringh TE, Dorland L, Bruinvis L, et al. Octanoylglucuronide excretion in patients with a defective oxidation of medium-chain fatty acids. Clin Chim Acta. 1985;152:253–260
  21. Koopmanschap MA, Rutten FFH, Van Ineveld BM, Van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14:171–189
  22. Statistics Netherlands (CBS) [homepage on the Internet]. Voorburg/Heerlen; 2006 [cited March 2006] Population. Available from: http://www.cbs.nl/en-GB/menu/themas/mens-maatschappij/bevolking/cijfers/default.htm, 2006.
  23. Pourfarzam M, Morris A, Appleton M, Craft A, Bartlett K. Neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency. Lancet. 2001;358:1063–1064
  24. Niezen-Koning KE, Chapman TE, Mulder IE, Smit GP, Reijngoud DJ, Berger R. Determination of medium chain acyl CoA dehydrogenase activity in cultured skin fibroblasts using mass spectrometry. Clin Chim Acta. 1991;199:173–184
  25. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Diemen: College voor zorgverzekeringen; 2004;Updated ed.
  26. Bittles AH, Petterson BA, Sullivan SG, Hussain R, Glasson EJ, Montgemory PD. The influence of intellectual disability on life expectancy. J Gerontol. 2002;57A:M470–M472
  27. Andresen BS, Dobrowolski SF, O’Reilly L, Muenzer J, McCandless SE, Frazier DM, et al. Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet. 2001;68:1408–1418
  28. Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem. 2001;47:1945–1955
  29. Buxton MJ. How much are health-care systems prepared to pay to produce a QALY?. Eur J Health Econom. 2005;6:285–287
  30. Schoen EJ, Baker JC, Colby CJ, To TT. Cost-Benefit Analysis of Universal Tandem Mass Spectrometry for Newborn Screening. Pediatrics. 2002;11:781–786

 Supported by ZonMw.

PII: S0022-3476(07)00249-1

doi: 10.1016/j.jpeds.2007.03.013

The Journal of Pediatrics
Volume 151, Issue 2 , Pages 115-120.e3 , August 2007

Article Tools

* Image Usage & Resolution